ID: h-255db681
Hypothesis
HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis
HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 5 oppose
🧪 Overview
HDAC6 Inhibitor Therapy for Pan-Neurodegenerative Protein Homeostasis
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["HDAC6<br/>Inhibition"]
B["Alpha-tubulin<br/>Acetylation Increase"]
C["Microtubule<br/>Stabilization"]
D["Autophagy<br/>Flux Restoration"]
E["Proteostasis<br/>Improvement"]
F["Pan-neurodegenerative<br/>Protein Clearance"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports5 contradicts
Supports
Decreased H3K9ac at autophagy gene promoters in AD prefrontal cortex correlates with reduced BECN1 expression
Supports
Pan-HDAC inhibition shows neuroprotection in ALS models through autophagy enhancement
Supports
DNA methylation age acceleration correlates with reduced autophagy pathway activity across neurodegenerative diseases
Supports
HDAC6-selective compounds (ACY-1215) have acceptable safety profiles in oncology trials
Contradicts
Evidence-base conflates pan-HDAC and selective HDAC6 inhibition - PMID:28161408 uses pan-HDAC, not HDAC6-selective
Contradicts
HDAC6 knockout mice demonstrate unexpected phenotypes including enhanced fear conditioning and altered synaptic plasticity
Contradicts
BBB penetration problematic - hydroxamate moiety creates P-gp/BCRP substrate liability; brain concentrations <5% of plasma
Contradicts
Autophagy modulation is context-dependent - may be detrimental in advanced neurodegeneration where autophagic flux is maximally engaged
Contradicts
HDAC6 elevation could represent a protective compensatory response to protein aggregation stress
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HDAC6
No curated PDB or AlphaFold mapping for HDAC6 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HDAC6 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HDAC6.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0043
Events (7d)
1
Price History
▲9.8%💾 Resource Usage
LLM Tokens
34,738
$0.1042
Total Cost
$0.1042
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF early-stage Parkinson's disease patients receive HDAC6 inhibitor (ACY-738 or equivalent) at 50mg twice daily for 24 weeks, THEN CSF α-synuclein aggregate clearance rate will increase by ≥25% compar | ≥25% increase in α-synuclein clearance rate; stabilization or reduction of CSF NfL levels | — no observation — | pending | 0.35 |
| IF 5xFAD mice (Alzheimer's model) receive chronic HDAC6 inhibitor (tubastatin A, 10mg/kg/day) via osmotic pump for 8 weeks starting at 3 months of age, THEN soluble aggregated tau levels in cortical t | ≥30% reduction in soluble hyperphosphorylated tau aggregates in cortical brain regions | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF 5xFAD mice (Alzheimer's model) receive chronic HDAC6 inhibitor (tubastatin A, 10mg/kg/day) via osmotic pump for 8 weeks starting at 3 months of age, THEN soluble aggregated tau levels in cortical tissue will decrease by ≥30% compared to vehicle-treated controls, as measured by biochemical fractio
Predicted outcome: ≥30% reduction in soluble hyperphosphorylated tau aggregates in cortical brain regions
Falsification: No significant difference (p>0.05) in tau aggregation between HDAC6 inhibitor and vehicle groups after 8 weeks of treatment, or increase in tau pathology
pendingconf 35%
IF early-stage Parkinson's disease patients receive HDAC6 inhibitor (ACY-738 or equivalent) at 50mg twice daily for 24 weeks, THEN CSF α-synuclein aggregate clearance rate will increase by ≥25% compared to baseline, as measured by seed amplification assay (RT-QuIC), with concurrent reduction in neur
Predicted outcome: ≥25% increase in α-synuclein clearance rate; stabilization or reduction of CSF NfL levels
Falsification: CSF α-synuclein aggregate signal increases or remains unchanged; NfL levels rise by >15% indicating neuronal injury progression
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.